GSK and Pfizer sign joint venture, but will demerge after three years

Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK completes buyout of Novartis from joint venture

7 June 2018 GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Americas

Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit

24 February 2015 Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission, the agency has said.

More on this story

Big Pharma

GSK completes buyout of Novartis from joint venture

7 June 2018 GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Americas

Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit

More on this story

Big Pharma

GSK completes buyout of Novartis from joint venture

7 June 2018 GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Americas

Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit